Clinical trial · Observational
PET Study in Patients With Non-Hodgkin Lymphoma
Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well it predicts outcomes in patients who have undergone high-dose chemotherapy and autologous stem cell transplant for non-Hodgkin lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fluorine 18-fludeoxyglucose positron emission tomography | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Flourine 18-fluorodeoxyglucose PET
- description
- PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
- interventionNames
- Radiation: fluorine 18-fludeoxyglucose positron emission tomography
Primary outcomes (1)
- measure
- Correlation of sensitivity, specificity, positive predictive value, and negative predictive value of fluorine 18-fludeoxyglucose positron emission tomography scan with with patients' clinical outcomes.
- timeFrame
- from the date of stem cell transplant to date of clinical disease progression or to date of last follow-up
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- from date of stem cell transplant to date of clinical disease progression or date of last follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: DISEASE CHARACTERISTICS: * Diagnosis of non-Hodgkin lymphoma * Has undergone high-dose chemotherapy followed by autologous stem cell transplantation at Vanderbilt University between March 1997 and August 2005 * Has undergone fluorine 18-fludeoxyglucose PET within 70 days prior to and/or at approximately 30 days and 100 days after high-dose chemotherapy and autologous stem cell transplantation Exclusion Criteria: PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available